Currently, the “dual-channel” drug management system has become an important channel for hospital and external supply chain drug management. However, how to achieve more efficient drug management is still the main issue in current drug management. Therefore, in order to achieve more efficient drug management. A new “dual-channel” drug management system based on hospital information system was proposed, which uses deep bidirectional network and convolutional recurrent neural network models to identify and manage drugs. At the same time, the new system uses deconvolution and binarization methods to improve the accuracy of drug recognition. The research results show that the accuracy of drug recognition in the model can reach 95.68%, which is 13.33% higher than other models. At the same time, the recall rate was also improved by 14.89% compared to other models. After using the new system, the number of effective image recognitions increased by 10, and the hospital’s revenue growth increased by 7.43%. The new system has better drug management effects and can also improve drug sales efficiency. This has good guiding significance for hospital drug management research.
QianHMeixinNCaoH, et al.Construction of a closed-loop management model for operating room drugs based on an intelligent IoT system. China Pharm2024; 35(14): 1696–1700.
2.
MaHSunYNapingZ, et al.Application of information technology in drug management for institutional clinical trials. Chin J Hosp Pharm2023; 43(23): 2692–2695.
3.
YunyunZQianHYeJ, et al.Construction of a full-process closed-loop management system for the circulation of narcotic and psychotropic drugs in hospitals based on the construction of six-level electronic medical records. Chin J Modern Appl Pharm2023; 40(11): 1549–1555.
4.
YangWZhouGQiQ, et al.Construction and application of an intelligent management system for narcotic and psychotropic drugs in inpatient pharmacies based on the FMEA method. Chin J Modern Appl Pharm2023; 40(9): 1253–1259.
5.
WangXWeiDChenG, et al.Construction and application of an auxiliary drug management system for drug clinical trials. Chin J Hosp Pharm2022; 42(22): 2411–2414.
6.
QuYZuoLZhangS, et al.Comparative analysis of adverse events linked to PEG-rhG-CSF and rhG-CSF in real-world settings: disproportionate examination of the US Food and drug administration (FDA) adverse event reporting system (FAERS) database. Clin Ther47(8): 624–630.
7.
MaederSJeannetC. A comparative assessment of the FDA list of 93 HPHCs in aerosol generated by tobacco heating system 2.2 versus 3R4F reference cigarette smoke.
8.
MahadikKParvatamSRaoNM. Pharmaceutical adoption of microphysiological systems in India is contingent on their economics among other aspects. J Biosci2025; 50(2): 39.
9.
KabanLBPosnickJCKeithDA. RE: TMJ concepts patient-fitted temporomandibular joint reconstruction prosthesis system: results from a food and drug administration postmarket surveillance prospective cohort study. J Oral Maxillofac Surg; 83(5): 507.
10.
HuangSGuoZWangM, et al.Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. Expert Opin Drug Saf2023; 22: 175–181.
11.
NehaRBeulahEAnushaB, et al.Vemurafenib induced drug reaction with eosinophilia and systemic symptoms (DRESS): a disproportionality analysis in FAERS database. Curr Rev Clin Exp Pharmacol2021; 16: 168.
12.
Leibovit-ReibenZGodfreyHJedlowskiP, et al.Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. Melanoma Res2024; 35(2): 122–129.
13.
LaidlawMKJorgensenS. Exploring safety in gender-affirming hormonal treatments: an observational study on adverse drug events using the food and drug administration adverse event reporting system database. Ann Pharmacother2025; 59(5): 491–492.
14.
WangWHuHLuoXW, et al.Blockchain-enabled platform for the quality management of the ready-mixed concrete supply chain. Adv Manuf2025; 13(2): 362–376.
15.
KoritarovT. Blockchain-enabled supply chain management: implications for the land transportation sector. German International Journal of Modern Science/Deutsche Internationale Zeitschrift für Zeitgenössische Wissenschaft2024.
16.
ShamsuzzohaAMarttilaJHeloP. Blockchain-enabled traceability system for the sustainable seafood industry. Technol Analysis Strategic Manag2024; 36(11): 3891.
17.
LalithaGGuptaMArulSJ, et al.Blockchain-Enabled simulation and optimization for supply chain transparency. E3S Web Conf2024; 472: 9.
18.
HuWZhangQZhouP, et al.Design of a semi-automatic intelligent management cabinet and its application in the management of narcotic drugs in the anesthesiology department. J Nurs2022; 29(14): 73–76.
19.
PoweleitEAVinksAAMizunoT. Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing. Ther Drug Monit2023; 45(2): 143–150.
20.
ZhangXDengJLuoJ, et al.Appearance recognition of drugs based on object detection. Chin J Modern Appl Pharm2024; 41(7): 983–989.
21.
YangLWeiZLiuY, et al.Risk identification and response to the interface of hospital drug management based on medical failure mode and effect analysis. Chin J Hosp Pharm2024; 44(11): 1338–1344.
22.
WangYMingzhuM. Establishment and preliminary application of a YOLO-V5 deep learning prediction model for accurate identification of drug packaging boxes in outpatient and emergency departments. Herald Med2024; 43(4): 661–667.
23.
LeiSBianlingFBiqiR, et al.Information recognition and classification efficiency evaluation of drug complaint cases based on artificial intelligence. Herald Med2023; 42(10): 1589–1593.
24.
ZhangXXieYBaoP, et al.Exploration on the identification of occupational health risks of active pharmaceutical ingredients based on drug classification. Chin Health Resources2022; 25(5): 607–612.
25.
HineloRPodunggeRAmboH. The effect of reward and punishment implementation on employee performance at the Gorontalo Food and Drug Supervisory Office. Jurnal Ekonomi2023; 12(01): 833–839.
